GleamWall
中文EN

IONS IONIS PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 874015 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.7%
TTM net income YoY-113.2%
TTM EPS YoY-96.4%
Revenue 3-yr CAGR16.0%
Net income 3-yr CAGR—

Margins

Gross margin98.2%
Operating margin-58.8%
Net margin-56.9%
FCF margin-64.2%
EBITDA margin-57.4%

Returns

ROE-108.1%
ROA-18.4%
ROIC (approx.)-236.8%
Asset turnover0.32x

Leverage & solvency

Liabilities / assets86.5%
Debt / equity0.00x
Current ratio5.43x
Interest coverage-29.37x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.1%
Payout ratio—
Capex / revenue7.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$943.71M$705.14M
Cost of revenue$15.91M$11.21M
Gross profit$927.80M$693.92M
R&D expense$915.62M$901.53M
SG&A expense$393.87M$267.47M
Operating income-$381.68M-$475.08M
Interest expense$17.26M$16.99M
Pretax income-$379.60M-$460.07M
Income tax$1.79M-$6.17M
Net income-$381.39M-$453.90M
EBITDA-$371.68M-$465.47M
EPS (basic)-2.38-3.04
EPS (diluted)-2.38-3.04
Weighted avg. shares (diluted)160.01M149.51M
Balance sheet
Cash & equivalents$372.26M$242.08M
Short-term investments$2.31B$2.06B
Inventory$10.05M$12.51M
Current assets$2.99B$2.62B
PP&E, net$123.05M$94.25M
Total assets$3.52B$3.00B
Current liabilities$781.57M$309.32M
Short-term debt$432.12M$165,000
Long-term debt$1.33B$1.20B
Total debt$1.76B$1.20B
Total liabilities$3.03B$2.42B
Shareholders' equity$489.09M$588.35M
Net debt$1.39B$960.49M
Shares outstanding163.30M157.91M
Cash flow statement
Operating cash flow-$268.58M-$500.95M
Capital expenditure$51.44M$45.28M
Free cash flow-$320.03M-$546.23M
Investing cash flow-$277.78M-$134.03M
Financing cash flow$675.84M$478.06M
Depreciation & amortization$10.01M$9.61M
Stock-based compensation$133.87M$130.20M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.